Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Office Of Drug Safety Acting Director Is Ralph Lillie

Executive Summary

FDA Emergency Preparedness Officer Ralph Lillie is serving as acting director of the Office of Drug Safety in the Center for Drug Evaluation & Research as of Jan. 23

You may also be interested in...



FDA Gets Permanent Drug Safety Director In Advance Of Drug Center Overhaul

FDA's Office of Drug Safety will take on a higher profile position under a proposed reorganization of the Center for Drug Evaluation & Research

FDA Gets Permanent Drug Safety Director In Advance Of Drug Center Overhaul

FDA's Office of Drug Safety will take on a higher profile position under a proposed reorganization of the Center for Drug Evaluation & Research

FDA Office Of Drug Safety Director Could Be Named By Late Summer

FDA hopes to hire a permanent director for the Office of Drug Safety by late summer or early fall now that it has begun a nationwide search to fill the position

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS045303

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel